CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company dedicated to the discovery and development of RNA-targeting therapeutics that increase gene expression to treat genetic diseases. The company’s proprietary RAP Platform enables systematic identification of regulatory RNAs that modulate transcription, allowing the design of antisense oligonucleotides intended to raise protein levels in conditions characterized by haploinsufficiency. Its primary therapeutic focus is on central nervous system disorders where restoring protein function may address significant unmet medical need.

CAMP4 Therapeutics derives revenue principally from collaboration and licensing agreements that provide upfront payments, milestone payments, and royalties on future product sales. In December 2025 the company entered into a research collaboration and license agreement with GlaxoSmithKline that includes an initial $17.5 million payment, potential development and commercial milestones totaling up to $440 million, and tiered royalties ranging from low to mid single digits on net sales of licensed products. The agreement covers antisense oligonucleotide therapeutics targeting regulatory RNAs associated with neurodegenerative and kidney disease indications. Additionally CAMP4 Therapeutics maintains a license with the Whitehead Institute for technologies related to gene expression modulation, for which it has paid modest upfront and annual fees but does not receive revenue. No product sales have been realized to date because its drug candidates remain in preclinical or early clinical stages.

CAMP4 Therapeutics occupies a distinct position in the oligonucleotide therapeutics arena by pursuing a strategy of gene upregulation through targeting regulatory RNAs, whereas many competitors concentrate on gene inhibition or splicing alteration. Competitors active in the central nervous system antisense oligonucleotide field include Stoke Therapeutics, Acadia Pharmaceuticals, Praxis Precision Medicines, GondolaBio, Tevard Biosciences, Regel Therapeutics, and Quiver Bioscience. The company’s competitive edge stems from its proprietary RAP Platform which has mapped tens of thousands of regulatory RNA sequences and employs a machine learning algorithm named EPIC to pinpoint the most relevant targets for therapeutic intervention. This capability provides a barrier to replication and supports rapid expansion of its pipeline across multiple tissue types. Moreover the company’s focus on haploinsufficient diseases addresses a large pool of rare and prevalent conditions for which no approved disease-modifying therapies currently exist.

The company’s current customers consist of its collaboration partner GlaxoSmithKline and the Whitehead Institute from which it licenses foundational technology. Looking ahead the intended customers will be patients diagnosed with rare genetic disorders such as SYNGAP1 related epileptic encephalopathy and urea cycle disorders, healthcare providers who prescribe treatments, and payors that reimburse for approved therapies. CAMP4 Therapeutics estimates that approximately 21,000 individuals live with SYNGAP1 in the United States and the five largest European markets, and it also notes about 2,000 diagnosed female ornithine transcarbamylase heterozygotes in the United States who may benefit from its urea cycle program.